JW Lifescience Corporation provides national infusion solutions in South Korea and internationally. The company offers basic intravenous fluid that comprises water, electrolytes, and glucose; nutrient infusion solution that consist of nutrients, such as amino acids, lipids, proteins, vitamins, and minerals; and special infusion solutions. The company was formerly known as JW Co. Ltd. and changed its name to JW Lifescience Corporation in April 2011. JW Lifescience Corporation was founded in 1994 and is based in Dangjin-si, South Korea.
Research context
JW Lifescience Corporation appears in PyInvesting’s Korea Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- KRW
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
5 years, 6 months ago
JW Lifescience Corporation is currently in a long term downtrend where the price is trading 3.4% below its 200 day moving average.
From a valuation standpoint, the stock is 81.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.6.
JW Lifescience Corporation's total revenue rose by 0.2% to $45B since the same quarter in the previous year.
Its net income has dropped by 216.6% to $-6B since the same quarter in the previous year.
Finally, its free cash flow grew by 947.6% to $19B since the same quarter in the previous year.
Based on the above factors, JW Lifescience Corporation gets an overall score of 3/5.